|
Volumn 14, Issue 8, 2003, Pages 1161-1162
|
ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTHRACYCLINE DERIVATIVE;
ANTINEOPLASTIC AGENT;
ARSENIC TRIOXIDE;
CYTARABINE;
HLA ANTIGEN;
RETINOIC ACID;
ACUTE MYELOBLASTIC LEUKEMIA;
ADULT;
AGE;
ARTICLE;
BLOOD ANALYSIS;
BLOOD EXAMINATION;
BONE MARROW BIOPSY;
BONE MARROW TRANSPLANTATION;
CANCER INCIDENCE;
CANCER MORTALITY;
CANCER PATIENT;
CANCER RECURRENCE;
CELL STRUCTURE;
CHROMOSOME ANALYSIS;
CYTOCHEMISTRY;
EUROPE;
FAMILY STUDY;
FOLLOW UP;
HEALTH CARE ORGANIZATION;
HEALTH STATUS;
HLA TYPING;
HUMAN;
IMMUNOPHENOTYPING;
KARYOTYPE;
LEUKAPHERESIS;
LEUKOCYTE COUNT;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
PROGNOSIS;
RISK ASSESSMENT;
STEM CELL TRANSPLANTATION;
TREATMENT FAILURE;
TREATMENT OUTCOME;
TREATMENT PLANNING;
ADULT;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BONE MARROW TRANSPLANTATION;
COMBINED MODALITY THERAPY;
FEMALE;
FOLLOW-UP STUDIES;
HEALTH PLANNING GUIDELINES;
HUMANS;
LEUKEMIA, MYELOCYTIC, ACUTE;
MALE;
MIDDLE AGED;
PATIENT CARE PLANNING;
REMISSION INDUCTION;
RISK ASSESSMENT;
SEVERITY OF ILLNESS INDEX;
TREATMENT OUTCOME;
|
EID: 0042385047
PISSN: 09237534
EISSN: None
Source Type: Journal
DOI: 10.1093/annonc/mdg337 Document Type: Article |
Times cited : (3)
|
References (4)
|